TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sleep onset timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bedtime compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of frailty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pennation angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: performance on the walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial nerve injury severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cumulative AF burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ASKp score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: difficulty with bathing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: long-term rate of fatal or disabling stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in pain on a scale of 0-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h TSH secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Circulating free T3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Timing functions performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cross-modal processing of visual-tactile stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vocal function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative granuloma
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence rate of pneumonia
Endpoint domain: Mortality/survival
Primary endpoint: Median time to recurrence of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: calculus formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reduction in absolute liver volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in mean body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in insulin-like growth factor 1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: confidence in managing depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gastric residue rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Feeding intolerance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain of attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse reactions related to drug placement
Endpoint domain: Adverse events/effects
Primary endpoint: Functional bowel disorder diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neuroticism scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostaglandin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RF IgM levels change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: systemic clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of distribution in the central compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intercompartmental clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HOMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Regression of thoracic plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of gestational diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: oral glucose tolerance test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GRV improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: median overall survival (mOS)
Endpoint domain: Mortality/survival
Primary endpoint: ASAS20/40 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from time zero to the last sampling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of ARR
Endpoint domain: Adverse events/effects
Primary endpoint: Synovitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone edema scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall sleep efficiency (SE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DCR at week 8
Endpoint domain: Mortality/survival
Primary endpoint: Schirmer test value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resolution of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vital lung capacity (VLC) unaltered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chest excursion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: standardized body mass index (zBMI) decreases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean rate of recruitment of eligible candidates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Six minutes walking distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Modified British Medical Research Council (MMRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median retention rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevention of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean overall hospitalisation length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean disease management cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: TCD improvement of basilar artery, vertebral artery and posterior inferior cerebellar artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complications related to anticoagulation therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Knee flares within 5 days of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Arthroscopic synovitis at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of knee symptoms over 91 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biliary complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: anastomotic strictures
Endpoint domain: Adverse events/effects
Primary endpoint: biliary complication-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Number of hospitalizations for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Number of hospitalizations for any cause
Endpoint domain: Mortality/survival
Primary endpoint: Quality-adjusted life years (QALYs) gain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: FLO-11 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SPA measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvements in tumor related symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Survival rates without stroke or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Repeat revascularization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stroke mortality
Endpoint domain: Mortality/survival
Primary endpoint: Percent reduction of S mutans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-traumatic stress symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emotional and behavioural difficulties in children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glottic visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Segmental spine movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with asthma care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bioequivalence of citalopram formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of technical problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time required for performance of CSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total dose of local anaesthetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of patients achieving 34 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Fetal ductus arteriosus constriction
Endpoint domain: Adverse events/effects
Primary endpoint: Oligohydramnios
Endpoint domain: Adverse events/effects
Primary endpoint: vascularity component of the VSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of in situ thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Postprandial elevation of triglycerides (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial elevation of apolipoproteins B‐48 and CIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial elevation of RLP‐cholesterol and RLP‐triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to appropriate device therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of units recalled from evaluative threat passages
Endpoint domain: Cognitive functioning
Primary endpoint: 2-year cumulative rate of brain metastasis
Endpoint domain: Mortality/survival
Primary endpoint: 2-year overall survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Duration of transition to total oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in beta-cell function (AIRg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in insulin secretion (DI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postprocedural pain reduction (PPPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bodily Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Role Physical
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Detection of P. jirovecii DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CBVD mortality
Endpoint domain: Mortality/survival
Primary endpoint: Relapse of symptomatic cryptococcal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Probability of remaining relapse-free at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious drug-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean post-preparation scroll widths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interpersonal violence victimization rates
Endpoint domain: Adverse events/effects
Primary endpoint: Interpersonal violence perpetration rates
Endpoint domain: Adverse events/effects
Primary endpoint: total faecal SCFA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in hyperaemia after heating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increase in skin blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Amount of oxytocin needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cervical maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mortality rate in patients with bilateral infiltrates and PaO2/FIO2 ≤ 300 mm Hg
Endpoint domain: Mortality/survival
Primary endpoint: number of patients with visual acuity >= 0.8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ipsilateral strokes
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from 70% or greater re-stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Duration of LMA insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival with initial PD catheter
Endpoint domain: Mortality/survival
Primary endpoint: Rate of second PCNL
Endpoint domain: Adverse events/effects
Primary endpoint: Stone clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Divided attention task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in motor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum alkaline phosphatase concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sero-prevalence of anti-HBc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative gastric volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intraoperative blood loss volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative blood loss volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: suppression of free IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: skin prick wheal responses to allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in ERPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endothelial dysfunction improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse events related to medication intake or therapy interruption
Endpoint domain: Adverse events/effects
Primary endpoint: CD4 cell count < 350 cells/microl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: irreversible graft failure
Endpoint domain: Mortality/survival
Primary endpoint: serious acute endothelial immune reaction
Endpoint domain: Adverse events/effects
Primary endpoint: elevated liver enzymes
Endpoint domain: Adverse events/effects
Primary endpoint: median time to progression of prostate-specific antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median time to progression of alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median time to progression of osteoblastic bone deposition markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No subjective stress leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative stress test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke or death events
Endpoint domain: Mortality/survival
Primary endpoint: Number of acid reflux events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postprandial acid exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Agreement with water volumetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue antiemetic requirements
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Strictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ristocetin-stimulated platelet activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Global health status/QoL improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median time to global health status/QoL deterioration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: subjective ratings of Good Effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Capsule passage status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cord blood 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain score on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Least pain scores on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of rescue oral analgesic required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TGF‐beta1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HMT time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: kaolin ACT time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma concentration of apo(a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PR of apo(a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total modified KI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total Menopause-Specific Quality of Life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fentanyl consumption at postoperative 2nd hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life in role physical profile
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in Roland-Morris questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: maximum IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: SD of IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: range of IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: improvement of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of pain due to osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to state date of birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: self-reported risky sexual behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound-healing problems
Endpoint domain: Adverse events/effects
Primary endpoint: Median time to return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Functional outcome score (CNF scale)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Children's development quotient (DQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes